November 13, 2017 | Israeli regenerative medicine company Collplant has raised about $7.4 million in private placement due to a number of filings submitted by the company to the Tel Aviv Stock Exchange over the past three months, according to a report in Calcalist. In November, the Ness Ziona-based company announced a private placement agreement with Ami Sagi, father of Israeli-born businessman Teddy Sagi. The agreement was worth $1.05 million. They also announced an agreement with Israeli investment company Meitav Dash Investments for $1.34 million. In September, the company had a private investment agreement of $5 million signed with Alpha Capital Anstalt of Lichtenstein. In June of this year, Collplant filed a U.S. patent application for a collegen-based bio-ink for “3D printing of tissues and organs.” The company wants to establish its ink in the market and is negotiating with companies in organ printing. Collplant develops medical treatments using plant-based collagen. Human collagen can be harvested from a plant that is created with a combination of human genes and tobacco plant DNA. The company was founded in 2004 by Oded Shosheyov.